Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet

Biochemical and Biophysical Research Communications

Volumn 492, Issue 2, 2017, Pages 161-165

  Hira, Tohru ^a   Koga, Toshiki ^a   Sasaki, Kazuyo ^b   Hara, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Canagliflozin; Diet induced obesity; Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; SGLT2 inhibitor; Sodium glucose cotransporter 1(SGLT1)

Indexed keywords

CANAGLIFLOZIN; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 1; ANTIDIABETIC AGENT; CARBOHYDRATE DIET; GLUCOSE BLOOD LEVEL; INCRETIN; INSULIN; SUCROSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOHYDRATE DIET; CONTROLLED STUDY; DISEASE MODEL; DRUG DOSE COMPARISON; ENTEROENDOCRINE CELL; GLUCOSE TRANSPORT; HORMONE BLOOD LEVEL; HORMONE RELEASE; IN VITRO STUDY; INHIBITION KINETICS; LIPID DIET; LOADING DRUG DOSE; MALE; MOUSE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT; SMALL INTESTINE; SYSTEMIC CIRCULATION; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CELL LINE; GLUCOSE BLOOD LEVEL; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD GLUCOSE; CANAGLIFLOZIN; CELL LINE; DIET, HIGH-FAT; DIETARY CARBOHYDRATES; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; MALE; OBESITY; RATS; RATS, SPRAGUE-DAWLEY; SODIUM-GLUCOSE TRANSPORTER 1; SUCROSE;

EID: 85027691344     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2017.08.031     Document Type: Article

References (28)

1. Drucker, D.J., Deciphering metabolic messages from the gut drives therapeutic innovation: the 2014 Banting Lecture. Diabetes 64 (2015), 317–326.
2. Holst, J.J., Incretin hormones and the satiation signal. Int. J. Obes. (Lond) 37 (2013), 1161–1168.
3. Drucker, D.J., The biology of incretin hormones. Cell Metab. 3 (2006), 153–165.
4. Miyawaki, K., Yamada, Y., Ban, N., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8 (2002), 738–742.
5. Hira, T., Muramatsu, M., Okuno, M., et al. GLP-1 secretion in response to oral and luminal palatinose (isomaltulose) in rats. J. Nutr. Sci. Vitaminol. (Tokyo) 57 (2011), 30–35.
6. Hira, T., Mochida, T., Miyashita, K., et al. GLP-1 secretion is enhanced directly in the ileum but indirectly in the duodenum by a newly identified potent stimulator, zein hydrolysate, in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 297 (2009), G663–G671.
7. Mochida, T., Hira, T., Hara, H., The corn protein, zein hydrolysate, administered into the ileum attenuates hyperglycemia via its dual action on glucagon-like peptide-1 secretion and dipeptidyl peptidase-IV activity in rats. Endocrinology 151 (2010), 3095–3104.
8. Hira, T., Suto, R., Kishimoto, Y., et al. Resistant maltodextrin or fructooligosaccharides promotes GLP-1 production in male rats fed a high-fat and high-sucrose diet, and partially reduces energy intake and adiposity. Eur. J. Nutr., 2017, 10.1007/s00394-017-1381-7.
9. Nauck, M.A., Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des. Devel Ther. 8 (2014), 1335–1380.
10. Rosenthal, N., Meininger, G., Ways, K., et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann. N. Y. Acad. Sci. 1358 (2015), 28–43.
11. Grempler, R., Thomas, L., Eckhardt, M., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes. Metab. 14 (2012), 83–90.
12. Liang, Y., Arakawa, K., Ueta, K., et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One, 7, 2012, e30555.
13. Gorboulev, V., Schurmann, A., Vallon, V., et al. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61 (2012), 187–196.
14. Parker, H.E., Habib, A.M., Rogers, G.J., et al. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 52 (2009), 289–298.
15. Wright, E.M., Loo, D.D., Hirayama, B.A., Biology of human sodium glucose transporters. Physiol. Rev. 91 (2011), 733–794.
16. Oguma, T., Nakayama, K., Kuriyama, C., et al. Intestinal sodium glucose cotransporter 1 inhibition enhances glucagon-like Peptide-1 secretion in normal and diabetic rodents. J. Pharmacol. Exp. Ther. 354 (2015), 279–289.
17. Oguma, T., Kuriyama, C., Nakayama, K., et al. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats. J. Pharmacol. Sci. 127 (2015), 456–461.
18. Oguma, T., Kuriyama, C., Nakayama, K., et al. Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium-glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents. J. Pharmacol. Sci. 132 (2016), 255–261.
19. Polidori, D., Sha, S., Mudaliar, S., et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 36 (2013), 2154–2161.
20. Nakajima, S., Hira, T., Hara, H., Postprandial glucagon-like peptide-1 secretion is increased during the progression of glucose intolerance and obesity in high-fat/high-sucrose diet-fed rats. Br. J. Nutr. 113 (2015), 1477–1488.
21. Reeves, P.G., Components of the AIN-93 diets as improvements in the AIN-76A diet. J. Nutr. 127 (1997), 838s–841s.
22. Kato, M., Tani, T., Terahara, N., et al. The anthocyanin delphinidin 3-rutinoside stimulates glucagon-like Peptide-1 secretion in murine GLUTag cell line via the Ca2+/Calmodulin-Dependent kinase II pathway. PLoS One, 10, 2015, e0126157.
23. Mortensen, K., Christensen, L.L., Holst, J.J., et al. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul. Pept. 114 (2003), 189–196.
24. Vilsboll, T., Krarup, T., Sonne, J., et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 88 (2003), 2706–2713.
25. Guo, D.Y., Li, D.W., Ning, M.M., et al. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models. Biochem. Biophys. Res. Commun. 466 (2015), 740–747.
26. Pham, H., Hui, H., Morvaridi, S., et al. A bitter pill for type 2 diabetes? The activation of bitter taste receptor TAS2R38 can stimulate GLP-1 release from enteroendocrine L-cells. Biochem. Biophys. Res. Commun. 475 (2016), 295–300.
27. Fukuoka, D., Okahara, F., Hashizume, K., et al. Triterpene alcohols and sterols from rice bran lower postprandial glucose-dependent insulinotropic polypeptide release and prevent diet-induced obesity in mice. J. Appl. Physiol. 117 (2014), 1337–1348.
28. Svendsen, B., Pedersen, J., Albrechtsen, N.J., et al. An analysis of cosecretion and coexpression of gut hormones from male rat proximal and distal small intestine. Endocrinology 156 (2015), 847–857.